Thomas Huenig
Directeur/Membre du Conseil chez TeGenero AG
Postes actifs de Thomas Huenig
Sociétés | Poste | Début | Fin |
---|---|---|---|
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Directeur/Membre du Conseil | 01/06/2000 | - |
Historique de carrière de Thomas Huenig
Formation de Thomas Huenig
Wuerzburg Schweinfurt University of Applied Sciences | Doctorate Degree |
Statistiques
Internationale
Allemagne | 3 |
Opérationnelle
Director/Board Member | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
- Bourse
- Insiders
- Thomas Huenig
- Expérience